secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000950170-22-020834
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end
--------------------------------------------------------------------------------

- CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.
- Exa-cel rolling FDA review starts Nov; complete submission due Q1 2023; EMA/MHRA submissions by year-end.
- CTX112 (next-gen CAR-T) IND cleared; Phase 1 expected H1 2023.
- VCTX211 (T1D stem-cell therapy) CTA cleared by Health Canada.
- CTX110 pivotal trial ongoing; CTX130 RMAT designation for CTCL; additional data expected in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/0000950170-22-020834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/crsp-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer